19th June 2020

(1) BSE Ltd

Listing Department

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai - 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Ltd

Listing Department

Exchange Plaza, 5th floor,

Plot no. C/1, G Block, Bandra Kurla Complex,

Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG

Societe Anonyme

35A Boulevard Joseph II,

L-1840 Luxembourg

Sub: Newspaper publication of Notice to shareholders whose shares are liable to be transferred to IEPF

Dear Sirs,

Please find enclosed herewith copies of newspaper advertisement published in Business Standard

(English) and Sakal (Marathi) on 19th June 2020.

The above notice is for shareholders who have not claimed their dividend(s) for seven consecutive years

or more and consequently whose shares are liable for transfer to the IEPF as per section 124(6) of the

Companies Act, 2013 read with the Investor Education and Protection Fund Authority (Accounting, Audit,

Transfer and Refund) Rules, 2016 notified by the Ministry of Corporate Affairs and subsequent

amendment(s) from time to time.

This is for your information and records.

Kindly acknowledge the receipt.

Thank you,

For Cipla Limited

Rajendra Chopra

Company Secretary

Prepared by: Raviraj Soni

MUMBAI | FRIDAY, 19 JUNE 2020 BRAND WORLD 13. <

VIVEAT SUSAN PINTOMumbai, 18 June

Among the lasting lifes-tyle changes that thepandemic is expected to

bring about is the increased andfrenzied focus on hygiene,reflected not just in the incr-eased demand personal careproducts and safety gear (suchas masks, gloves and protectiveclothing), but also for cleaningagents, such as floor and sur-face sanitizers and cleaners.And leading consumer goodscompanies such as HindustanUnilever (HUL), ITC and RB(earlier Reckitt Benckiser) areresponding to the shift in con-sumer behaviour with a sharpfocus on their portfolio of clean-ing brands, with new cam-paigns and also new productsthat promise to address the con-cerns raised by the pandemic.

As people work from homeand increasingly come to termswith restricted living inducedby the Covid-19 pandemic, thewar on germ-kill, say experts,has taken new dimensions, withmany now seeking productsthat can offer better anti-germproperties across platforms.HUL has been running a cam-paign for its cleaning brandDomex that claims to removethe Covid-19 virus from all sur-faces if used for a minute. RB,maker of Dettol, Harpic, andLizol, has been running a highdecibel campaign on surfacecleaning and ITC has beenactively promoting its brandSavlon on multiple platforms.

A recent Nielsen Indiareport says that segments suchas floor and toilet cleaners havedoubled their rate of growth (to24 per cent) in March-April ver-sus January-February. Another

study by ad agencyWunderman Thompson onconsumer behaviour in Indiaduring the lockdown shows that86 per cent people surveyed (in32 cities across 15 states) saidthat if floor and kitchen cleanerscame with better anti-germ ben-efits, they would purchase theproduct. The study also saidthat 85 per cent of the respon-dents were open to the idea ofpurchasing detergents that hadanti-germ properties in them.

The Covid-19 pandemic, asK V Sridhar, global chief creativeofficer, Nihilent Hypercollectiveexplains, has accelerated theshift from personal to homehygiene. “The war on germs hasextended to everything involvedin a consumer’s life as peopleendeavour to keep safe in ahealth crisis,” he says.

The pandemic has intensi-fied interest in the category ofcleaning products, which is like-ly to transform long term behav-iour towards such products andbrands. Ajeeta Bharadwaj,national planning director,Wunderman Thompson India,says that the Covid-19 pandem-ic has led to “structuralchanges” in mindsets and mar-

ketplaces alike. “It is forcing arethink on the way things havebeen done so far at a scale that ishard to imagine,” she adds.

Marketers are picking up thecues quickly. Hence the cam-paign for Domex highlights itsdisinfectant properties and thepresence of sodium hypochlo-rite, a bleach recommended bythe World Health Organizationas an effective germ-killer.“There are a new set of con-sumers who’ve emerged ashygiene warriors due to the pan-demic. They want complete dis-infection of the spaces aroundthem and are seeking productsthat help them in this regard.Domex has sodium hypochlo-rite that is effective when itcomes to germ and virus kill.We've also tested the product atan ISO-certified laboratory inthe US to establish that Domexkills germs in 60 seconds,” saysPrabha Narasimhan, executivedirector, homecare, HUL.

ITC, the makers of Savlonand Nimyle, both hygienebrands, has also amplified theirgerm-kill properties to suit thenew consumer. In an interviewto Business Standard this week,B Sumant, executive director,

ITC, said that the company hadwitnessed significant demandfor surface cleaning products,prompting the company tolaunch Savlon disinfectantspray as well as Savlon germprotection wipes during thelockdown. RB has sought outcelebrity power to turn the spot-light on it portfolio of brands(Dettol, Harpic, and Lizol). SaifAli Khan and Kareena Kapooras well as Genelia and RiteishDeshmukh are the faces for its#DisinfectToProtect campaignthat urges consumers to disin-fect surfaces frequently.

Sukhleen Aneja, chief mar-keting officer and marketingdirector, RB Hygiene South Asia,says that at this time both pro-tection and precaution are key tofighting viruses. “It has becomeextremely critical to maintaingood hygiene at home. With thecampaign, we want to raiseawareness about the need fordisinfecting not just floors butmultiple surfaces,” she says. Inthe coming months, the focuson the category will stay sharpand also, experts point out, thereare likely to be a flurry of brandextensions and innovations towiden the market further.

HUL, RB, ITCup the antein home hygieneBrands look to leverage the sharply rising consumer interest in externalcleanliness, launch new campaigns and products

(Clockwise from above) Lizol (RB) has roped incelebrity endorsers, Domex (HUL) claims it can kill allgerms on any surface, and Nimyle (ITC) promises tokeep the virus off all surfaces

SC seeks...Also, as sought by the court, DoT sub-mitted an affidavit explaining the reason forasking PSUs to pay AGR dues.

Senior advocate Mukul Rohatgi, appear-ing for Vodafone Idea, said the companyhad already paid ~7,000 crore to the DoT,but keeping in mind the “precarious” finan-cial condition, it was not in a position tofurnish any bank guarantee. Pointing outthat no bank will give it a loan, the compa-ny said it would have to fold up if asked topay the dues upfront. Payment in install-ment is the only way to remain a going con-cern, the company stated.

Vodafone Idea, which has AGR liabilitiesworth more than ~53,000 crore, had earlierpleaded for more time to pay the full dues.The company had on March 6 pegged itstotal dues to the government at ~21,533crore, while the Telecom Department esti-mated it at over ~53,000 crore. The compa-ny said it had paid in two instalments of~3,354 crore and ~3,500 crore towards AGRdues. Bharti Airtel, in its submission, said itshould be allowed to make the remainingAGR payments in 20 years as the companywas a well-established player in the tele-com space and not a fly-by-night operator.In the affidavit, Bharti Airtel and BhartiHexacon have said that they have alreadypaid a sum of ~18,004 crore to the DoT,which is 62 per cent of the total amountreceived by the department from all opera-tors, in compliance with the judgement.The two telcos said that no additional secu-rity should be charged from them duringthe proposed 20-year payment period. In a

letter to the DoT on March 6, the Bharticompanies had explained how these pay-ments discharged the liabilities of the twofirms. DoT has ~10,800 crore of bank guar-antees available with it from the compa-nies. “The Bharti companies are not fly-by-night operators and have operations in 16countries having 423 million subscribers,”the affidavit said.

On June 11, the Supreme Court (SC) haddirected Bharti Airtel and Vodafone Ideato file a reply on the roadmap of payment,time to be allowed, and securities.

On the 20-year payment term soughtby the telcos, the SC had said recently,“Can’t allow extension based on a gentle-man’s promise. How can 20 years be said tobe reasonable?”

The SC had on October 24, 2019, upheldDoT’s definition of AGR, ending the 14-year-old legal battle between telecom oper-ators and the government.

According to official estimates, 16 tele-com entities owe the government ~1.47 tril-lion in AGR liabilities — ~92,642 crore inlicence fee and another ~55,054 crore inoutstanding spectrum usage charges.

Many of the 16 entities which were sentnotices for payment of AGR dues haveeither shut their business, sold off to othersor gone into bankruptcy.

On a self-assessment pattern, BhartiAirtel paid ~13,004 crore to the governmentin two installments. It had also deposited anadditional ~5,000 crore as an ad-hoc pay-ment to cover any reconciliation differ-ences. However, DoT estimates show thecompany has to pay ~35,500 crore.

Tata Teleservices paid ~2,197 crore inAGR dues, followed by an additional ~2,000crore to cover reconciliation differences,

against the DoT estimate of thecompany’s liabilities at ~14,000crore. On June 11, SC hadslammed the DoT for includingnon-telecom PSUs in the AGRcase when its verdict of October24, 2019, was silent on state-owned units. The DoT had askedPSUs to pay licence fee and spec-trum usage charge dues, not onlyon telecom-related revenues buton total revenues.

Made-in-India...In the first week of June, the firmgot approval for remdesivir fromthe Indian drug regulator.Indian licencees — Cipla,Hetero, Zydus Cadila, and DrReddy’s Laboratories — as wellas Dutch firm Mylan, which willmake the drug in India, are,however, yet to get a formal nodfrom the Drug ControllerGeneral of India (DCGI).

With the growing clamourfor the drug, states likeMaharashtra have consideredimporting it from companies inBangladesh. In some cases,individual patients have soughtthe drug regulator’s nod toimport the drug. Multiplesources now indicate thatremdesivir would soon be avail-

able in India from domestic players.A senior executive of one of the licencees

said the Central Drugs Standard ControlOrganisation (CDSCO) had sought stabilitydata to ensure the drug was safe to use oncein the market. “The central drug testinglaboratory was to review the test batchessubmitted by the manufacturers for stabil-ity. If things go well, the approval can comein eight to 10 days, and the drug will beavailable in the market by the end of thismonth,” he said. He further added the drugwould be priced competitively in the Indianmarket and the price could be around~5000 for a dose. Each patient will needeleven doses, taking the cost of treatment toabout ~55,000.

Another licencee confirmed that thepricing of remdesivir would be around thatmuch, and added that market dynamicswould keep the price in check. “India is afairly efficient market in terms of competi-tion. Price will be a dynamic thing depend-ing on demand and supply, but it will not bea bottleneck for patients. Today a patient ispaying anything between ~35,000 and~60,000 a day in hospitals. This drugreduces at least three to four days of one’shospital stay. In that way, the drug will payfor itself,” he said.

Industry sources said pharma firms inBangladesh were importing the activepharmaceutical ingredients from Chinaand thus they were quoting a much higherprice — around ~10,000 for a vial.

A Gilead spokesperson had told BusinessStandard earlier that the primary purposeof filing the new drug application in Indiawas to support the voluntary licenceesbased in India. “The timeline to get remde-sivir to the Indian patients that need it willdepend on the licencees and a process thatGilead does not control. Our individuallicencees will also file applications with theCDSCO to manufacture and sell remdesivir,while waiving the requirement for under-taking local clinical trials,” the spokespersonhad said.

The Indian licencees have been in reg-ular contact with the CDSCO, which toowants to bring in the domestically madedrug into the market soon. A CDSCO sourcetold Business Standard that one has toweigh the safety and do a risk-benefit analy-sis in such a critical situation.

An industry source said the CDSCO hadasked for stability and toxicology data,which would be submitted “by the end ofthis week or so”.

Industry sources said if the DCGI didnot take a decision by next week based onthe data available to give approval to theIndian licencees, the next set of additionaldata would take at least 60 days to generate.

Meanwhile, pressure is mounting onthe government to make the drug availablehere soon. Sanjay Oak, leader of theMaharashtra task force of doctors on Covid-19, has requested the state government mul-tiple times to make the drug available soon.The state government thus consideredimporting it from companies inBangladesh, which do not have any licenceto make the injectable. “The drug is avail-able in the Indian market unfortunately.The risk is the product is not even approvedin Bangladesh,” said one of the companiesthat has Gilead’s licence.

> FROM PAGE 1

SOLUTION TO #3080 MMeeddiiuumm:: ������

Solution

tomorrow

HOW TO PLAY

Fill in the grid sothat every row,every columnand every 3x3box contains the digits 1 to 9

> BS SUDOKU # 3081